However, they did observe an increase in percentage of TIM-3 positivity on tumor-infiltrating CD4+ and CD8+ T cells compared to peripheral CD4+ and CD8+ T cells from both primary and recurrent glioblastoma patients [17]. This evidence concerns the gene CD4 and neoplasm.